UK-China partnerships against antimicrobial resistance get funding

On the day that the UK Government publishes its strategy to tackle antimicrobial resistance (AMR), the UK’s innovation agency, Innovate UK is announcing winners of two research competitions to address the issue of infections resistant to antibiotics both in humans and in animals.

On behalf of the Department of Health and Social Care (DHSC), Innovate UK has completed two research competitions that will award £20 million of research funding for AMR research. This includes a bilateral research competition between DHSC’s Global AMR Innovation Fund (GAMRIF) and the Chinese Ministry of Science and Technology (MoST), and a competition as part of the Small Business Research Initiative (SBRI).

GAMRIF’s UK-China research competition supports new innovations to address antimicrobial infections in both humans and animals, which together constitute a significant threat to human health. Successful projects are a partnership of UK companies and research organisations, with Chinese companies and research organisations. £10 million of UK aid funding has now been awarded to UK partners, with MoST providing funding for the Chinese partners who will receive up to a total of 60 million RMB.

These partnerships will enable novel research to be conducted that neither country could carry out alone within the same time frame.

In total, 14 projects were selected and will run over the next three years. These projects include a diverse range of innovations, such as novel diagnostics, therapeutics, and animal feed, as well as opportunities from traditional Chinese medicine for treating or preventing infectious bacterial disease.

The results of this research will have global implications including in China and across emerging and developing countries.

Among these projects, are a collaboration between The Vaccine Group, based in Plymouth and the Shanghai Veterinary Research Institute (SHVRI), Chinese Academy of Agricultural Science (CAAS), which plans to use a bovine virus as a safe, inexpensive, single dose vaccine to control Streptococcus suis infection in domestic pigs. Also working with SHVRI, CAAS is GAMA Healthcare Ltd in Watford, who have collaboratively proposed to develop a non-antibiotic treatment of multi-drug resistant organisms in poultry.

Professor Dame Sally Davies, England’s Chief Medical Officer, said:

Drug resistant infections claim hundreds of thousands of lives across the globe. An innovative and international response is vital – this latest collaboration between the UK and China guarantees much needed research to address the complex and world-wide issue of AMR

Dr Kath Mackay, Interim Director - Ageing Society, Health & Nutrition, Innovate UK said:

Antimicrobial resistance is one of the biggest global challenges in healthcare. It has been estimated that the AMR threat could lead to 10 million extra deaths a year and cost the global economy up to £75 trillion by 2050.

This partnership between China and the UK’s world-leading bio-industry is a vital contribution to tacking this issue through international co-operation.

A further £10 million has been awarded to UK organisations as part of the SBRI to develop solutions to AMR in humans. This competition focuses on two strands of research; new therapies and infection prevention and control.

Of the 13 projects selected across business and academia, 9 are led by small and medium enterprises who will translate AMR research into industry.

Winners include a project from Surrey-based Clean Blue Ltd that will develop an anti-infective medical device. Medisieve, based in London, has also received funding to use magnetic blood filtration to treat antibiotic resistant bacterial sepsis.

 

 

 

Source: GOV UK

https://www.gov.uk/government/news/uk-china-partnerships-against-antimicrobial-resistance-get-funding


PRIVACY

提示条款
iconfont平台提醒您:在使用iconfont平台各项服务前,请您务必仔细阅读并透彻理解本声明。如对本声明内容有任何疑问,您可通过网站下方公布的联系方式联系iconfont进行咨询。如果您不同意本声明或其中任何内容,您应立即停止使用iconfont平台服务。如果您使用iconfont平台服务的,您的使用行为将被视为对本声明全部内容的认可。
定义
iconfont平台:是一个矢量技术交流学习分享的平台,同时为广大用户提供矢量图标存储、字体图标转换等功能的平台(域名为iconfont.cn)。
iconfont:是iconfont平台运营方“淘宝(中国)软件有限公司”的简称。
权利归属
除非iconfont另行声明,除用户自行上传的内容外,iconfont平台内的所有产品、技术、软件、程序、数据及其他信息(包括但不限于文字、图像、图片、照片、音频、视频、图表、色彩、版面设计、电子文档)的所有权利(包括但不限于版权、商标权、专利权、商业秘密及其他所有相关权利)均归iconfont或其关联公司所有。未经iconfont许可,任何人不得擅自使用(包括但不限于通过任何机器人、蜘蛛等程序或设备监视、复制、传播、展示、镜像、上传、下载iconfont平台内的任何内容)。 iconfont平台的Logo、“iconfont.cn”等文字、图形及其组合,以及iconfont平台的其他标识、徵记、产品和服务名称均为iconfont及其关联公司在中国和其它国家的商标,未经iconfont书面授权,任何人不得以任何方式展示、使用或作其他处理,也不得向他人表明您有权展除非iconfont另行声明,除用户自行上传的内容外,iconfont平台内的所有产品、技术、软件、程序、数据及其他信息(包括但不限于文字、图像、图片、照片、音频、视频、图表、色彩、版面设计、电子文档)的所有权利(包括但不限于版权、商标权、专利权、商业秘密及其他所有相关权利)均归iconfont或其关联公司所有。未经iconfont许可,任何人不得擅自使用(包括但不限于通过任何机器人、蜘蛛等程序或设备监视、复制、传播、展示、镜像、上传、下载iconfont平台内的任何内容)。
iconfont平台的Logo、“iconfont.cn”等文字、图形及其组合,以及iconfont平台的其他标识、徵记、产品和服务名称均为iconfont及其关联公司在中国和其它国家的商标,未经iconfont书面授权,任何人不得以任何方式展示、使用或作其他处理,也不得向他人表明您有权展... 除非iconfont另行声明,除用户自行上传的内容外,iconfont平台内的所有产品、技术、软件、程序、数据及其他信息(包括但不限于文字、图像、图片、照片、音频、视频、图表、色彩、版面设计、电子文档)的所有权利(包括但不限于版权、商标权、专利权、商业秘密及其他所有相关权利)均归iconfont或其关联公司所有。未经iconfont许可,任何人不得擅自使用(包括但不限于通过任何机器人、蜘蛛等程序或设备监视、复制、传播、展示、镜像、上传、下载iconfont平台内的任何内容)。 iconfont平台的Logo、“iconfont.cn”等文字、图形及其组合,以及iconfont平台的其他标识、徵记、产品和服务名称均为iconfont及其关联公司在中国和其它国家的商标,未经iconfont书面授权,任何人不得以任何方式展示、使用或作其他处理,也不得向他人表明您有权展除非iconfont另行声明,除用户自行上传的内容外,iconfont平台内的所有产品、技术、软件、程序、数据及其他信息(包括但不限于文字、图像、图片、照片、音频、视频、图表、色彩、版面设计、电子文档)的所有权利(包括但不限于版权、商标权、专利权、商业秘密及其他所有相关权利)均归iconfont或其关联公司所有。未经iconfont许可,任何人不得擅自使用(包括但不限于通过任何机器人、蜘蛛等程序或设备监视、复制、传播、展示、镜像、上传、下载iconfont平台内的任何内容)。
iconfont平台的Logo、“iconfont.cn”等文字、图形及其组合,以及iconfont平台的其他标识、徵记、产品和服务名称均为iconfont及其关联公司在中国和其它国家的商标,未经iconfont书面授权,任何人不得以任何方式展示、使用或作其他处理,也不得向他人表明您有权展... 除非iconfont另行声明,除用户自行上传的内容外,iconfont平台内的所有产品、技术、软件、程序、数据及其他信息(包括但不限于文字、图像、图片、照片、音频、视频、图表、色彩、版面设计、电子文档)的所有权利(包括但不限于版权、商标权、专利权、商业秘密及其他所有相关权利)均归iconfont或其关联公司所有。未经iconfont许可,任何人不得擅自使用(包括但不限于通过任何机器人、蜘蛛等程序或设备监视、复制、传播、展示、镜像、上传、下载iconfont平台内的任何内容)。 iconfont平台的Logo、“iconfont.cn”等文字、图形及其组合,以及iconfont平台的其他标识、徵记、产品和服务名称均为iconfont及其关联公司在中国和其它国家的商标,未经iconfont书面授权,任何人不得以任何方式展示、使用或作其他处理,也不得向他人表明您有权展除非iconfont另行声明,除用户自行上传的内容外,iconfont平台内的所有产品、技术、软件、程序、数据及其他信息(包括但不限于文字、图像、图片、照片、音频、视频、图表、色彩、版面设计、电子文档)的所有权利(包括但不限于版权、商标权、专利权、商业秘密及其他所有相关权利)均归iconfont或其关联公司所有。未经iconfont许可,任何人不得擅自使用(包括但不限于通过任何机器人、蜘蛛等程序或设备监视、复制、传播、展示、镜像、上传、下载iconfont平台内的任何内容)。
iconfont平台的Logo、“iconfont.cn”等文字、图形及其组合,以及iconfont平台的其他标识、徵记、产品和服务名称均为iconfont及其关联公司在中国和其它国家的商标,未经iconfont书面授权,任何人不得以任何方式展示、使用或作其他处理,也不得向他人表明您有权展...